Search alternatives:
point decrease » point increase (Expand Search)
d decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
point decrease » point increase (Expand Search)
d decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
14921
-
14922
-
14923
Expression levels of myosin heavy chain and AMPK-PGC-1α pathway in the skeletal muscles.
Published 2016“…<p>The mRNA expression levels of <i>MYH1</i> (encoding MHC type IIx), <i>MYH2</i> (encoding MHC type IIa), and <i>MYH7</i> (encoding MHC type I) normalized to β2-microglobulin levels in the intercostal muscles of SBMA (<i>n</i> = 5) and ALS (<i>n</i> = 5) subjects (A–C). …”
-
14924
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…Current treatments, such as teriparatide, boost bone formation but also elevate resorption, limiting their long-term effectiveness. We discovered 3-butyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<i>d</i>]pyrimidin-4(3<i>H</i>)-one <b>(5cc)</b>, an orally active phosphodiesterase-1 (PDE1) inhibitor aimed at restoring this balance. …”
-
14925
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…Current treatments, such as teriparatide, boost bone formation but also elevate resorption, limiting their long-term effectiveness. We discovered 3-butyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<i>d</i>]pyrimidin-4(3<i>H</i>)-one <b>(5cc)</b>, an orally active phosphodiesterase-1 (PDE1) inhibitor aimed at restoring this balance. …”
-
14926
Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms
Published 2025“…Current treatments, such as teriparatide, boost bone formation but also elevate resorption, limiting their long-term effectiveness. We discovered 3-butyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<i>d</i>]pyrimidin-4(3<i>H</i>)-one <b>(5cc)</b>, an orally active phosphodiesterase-1 (PDE1) inhibitor aimed at restoring this balance. …”
-
14927
-
14928
Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study
Published 2015“…MR analyses found that each genetically determined one-standard-deviation decrease in log-transformed 25OHD level conferred a 2.0-fold increase in the odds of MS (95% CI: 1.7–2.5; <i>p</i> = 7.7 × 10<sup>−12</sup>; <i>I</i><sup>2</sup> = 63%, 95% CI: 0%–88%). …”
-
14929
-
14930
-
14931
PrioV3 and ICSM35 antibodies inhibit accumulation of PrP<sup>Sc</sup> in ScN2a cells.
Published 2013“…<p>ScN2a cells were incubated for 24 hours at 37°C (5% CO<sub>2</sub>) with 1 or 25 µg PrioV3 and ICSM35. 25 µg NCS (Normal camel serum), and BRIC126-treated as well as untreated cells were also included. …”
-
14932
LARP1 regulates Netrin-1 microsomal translation.
Published 2016“…LARP1 depletion decreases the expression of Netrin-1 protein in microsomes in Huh7.5 cells. …”
-
14933
-
14934
-
14935
-
14936
-
14937
Characterization of LNCaP cell growth cultured within biomimetic hydrogels in normal growth media, RPMI and 10% FBS.
Published 2012“…<p>(A) Growth curves of LNCaP cells over 7 days for 2D cultures (left) and 28 days for 3D cultures (right) in normal growth media measured by total DNA content (mean ± SE). …”
-
14938
Epidermal Growth Factor Receptor-Dependent Mutual Amplification between Netrin-1 and the Hepatitis C Virus
Published 2016“…Knockdown and forced expression experiments identified the receptor uncoordinated receptor-5 (UNC5A) as an antagonist of the Netrin-1 signal, though it did not affect the death of HCV-infected cells. …”
-
14939
-
14940
ACE conformation in lung cancer (conformational fingerprinting of ACE).
Published 2019“…Data presented as a mean of at least 2–3 independent experiments in duplicates. …”